Abstract： Objective： To systematically evaluate the efficacy and safety of Xinqin Granules combined with H1 Receptor Antagonist in the treatment of allergic rhinitis. Methods：The randomized controlled trials of the therapy of Xinqin Granules combined with H1 Receptor Antagonist in treating allergic rhinitis were searched from China National Knowledge Network (CNKI)， China Biomedical Medicine (CBM)， Wanfang Database (Wanfang)，VIP Database (VIP)，Cochrane Library，Embase and PubMed. A Meta-analysis was performed by using RevMan5.3 and Stata15.0 software. Results： A total of 7 papers were included， involving 683 patients. Meta-analysis showed that the total effective rate of the therapy of Xinqin Granules combined with H1 Receptor Antagonist in treating allergic rhinitis [RR=1.18，95%CI (1.11，1.25)，P＜0.000 1] was higher than that in the control group. The sensitivity score suggested that the therapy of Xinqin Granules combined with H1 Receptor Antagonist had a stable total effective rate on treating allergic rhinitis. The incidence recurrence of Xinqin Granules combined with H1 Receptor Antagonist was lower than that in the control group [RR=0.27，95%CI (0.12，0.61)，P=0.001]. There was no significant difference between the two groups in the incidence of adverse reactions [RR=0.61，95%CI (0.26，1.40)，P=0.24]. Conclusion： The therapy of Xinqin Granules combined with H1 Receptor Antagonist has a better therapeutic effect on the treatment of allergic rhinitis than the H1 Receptor Antagonist alone，which also has great safety.